NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CVKD Stock Alerts $0.49 -0.01 (-2.00%) (As of 11:43 AM ET) Add Compare Share Share Today's Range$0.49▼$0.5150-Day Range$0.39▼$0.7052-Week Range$0.36▼$3.14Volume67,613 shsAverage Volume365,357 shsMarket Capitalization$7.84 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cadrenal Therapeutics alerts: Email Address Cadrenal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside614.3% Upside$3.50 Price TargetShort InterestHealthy2.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.04% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently increased by 313.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVKD. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for CVKD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders58.12% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.92% of the stock of Cadrenal Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Shocks Millions With US Dollar LunacyDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Cadrenal Therapeutics Stock (NASDAQ:CVKD)Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Read More CVKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVKD Stock News HeadlinesApril 20, 2024 | finance.yahoo.comFavourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired StockApril 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024May 7, 2024 | Preserve Gold (Ad)Trump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?April 11, 2024 | prnewswire.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | marketwatch.comCadrenal Therapeutics Gets FDA Orphan Drug Designation for TecarfarinApril 9, 2024 | markets.businessinsider.comCadrenal Therapeutics: FDA Grants Orphan Drug Designation For Tecarfarin; Stock JumpsApril 9, 2024 | bizjournals.comPonte Vedra-based Cadrenal Therapeutics receives second FDA orphan drug designationApril 9, 2024 | prnewswire.comCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsMay 7, 2024 | Preserve Gold (Ad)Trump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?March 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)March 11, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finance.yahoo.comCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateFebruary 26, 2024 | prnewswire.comCadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceFebruary 14, 2024 | morningstar.comCadrenal Therapeutics Inc CVKDFebruary 8, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialFebruary 8, 2024 | finance.yahoo.comCadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialJanuary 31, 2024 | finance.yahoo.comCadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsJanuary 30, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 4, 2024 | finance.yahoo.comCadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceDecember 19, 2023 | benzinga.comCadrenal Therapeutics Stock (NASDAQ:CVKD), Analyst Ratings, Price Targets, PredictionsDecember 11, 2023 | uk.finance.yahoo.comCadrenal Therapeutics, Inc. (CVKD)November 30, 2023 | finance.yahoo.comCadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023November 21, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Cadrenal Therapeutics (CVKD) with Buy RecommendationNovember 9, 2023 | msn.comCadrenal Therapeutics reports Q3 resultsNovember 9, 2023 | finance.yahoo.comCadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateOctober 9, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceSee More Headlines Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/07/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVKD CUSIPN/A CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+600.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.67% Return on Assets-117.76% Debt Debt-to-Equity RatioN/A Current Ratio10.27 Quick Ratio10.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book0.85Miscellaneous Outstanding Shares16,010,000Free Float6,704,000Market Cap$8.01 million OptionableNot Optionable Beta1.64 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Douglas W. Losordo FACC (Age 66)FAHA, M.D., Chief Medical Officer Comp: $528.69kMr. Quang X. Pham (Age 59)Chairman & CEO Comp: $822.17kMr. Matthew K. Szot CPA (Age 50)CPA, Chief Financial Officer Comp: $359.61kMr. Jeffrey ColeChief Operating OfficerKey CompetitorsAyala PharmaceuticalsNASDAQ:ADXSPulmatrixNASDAQ:PULMPasithea TherapeuticsNASDAQ:KTTAAdial PharmaceuticalsNASDAQ:ADILTFF PharmaceuticalsNASDAQ:TFFPView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 568,000 shares on 2/13/2024Ownership: 3.182%John Raymond MurphyBought 17,331 shares on 10/4/2023Total: $12,131.70 ($0.70/share)Quang X PhamBought 70,000 shares on 9/1/2023Total: $63,700.00 ($0.91/share)View All Insider TransactionsView All Institutional Transactions CVKD Stock Analysis - Frequently Asked Questions Should I buy or sell Cadrenal Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CVKD shares. View CVKD analyst ratings or view top-rated stocks. What is Cadrenal Therapeutics' stock price target for 2024? 2 brokers have issued twelve-month price objectives for Cadrenal Therapeutics' stock. Their CVKD share price targets range from $3.00 to $4.00. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 614.3% from the stock's current price. View analysts price targets for CVKD or view top-rated stocks among Wall Street analysts. How have CVKD shares performed in 2024? Cadrenal Therapeutics' stock was trading at $0.7399 on January 1st, 2024. Since then, CVKD stock has decreased by 33.8% and is now trading at $0.49. View the best growth stocks for 2024 here. Are investors shorting Cadrenal Therapeutics? Cadrenal Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 173,700 shares, an increase of 313.6% from the March 31st total of 42,000 shares. Based on an average daily trading volume, of 421,400 shares, the short-interest ratio is currently 0.4 days. Approximately 2.0% of the company's stock are short sold. View Cadrenal Therapeutics' Short Interest. When is Cadrenal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CVKD earnings forecast. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) released its earnings results on Monday, March, 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVKD) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
